Company news

Lantheus Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting

November 2, 2026

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

September 30, 2026

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

September 22, 2026

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

August 14, 2026

Lantheus Reports Second Quarter 2026 Financial Results

August 6, 2026

Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8: 00 a.m. Eastern Time

July 23, 2026

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

June 26, 2026

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

June 1, 2026

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

May 27, 2026

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

May 21, 2026

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8: 00 a.m. Eastern Time

April 23, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

March 16, 2026

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

March 5, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

March 2, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Lantheus to Present at March 2026 Investor Conferences

February 24, 2026

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8: 00 a.m. Eastern Time

February 12, 2026

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

January 1, 2026

Lantheus to Present Florbetaben F 18 Data at CTAD 2025

November 23, 2025

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

November 5, 2025

Lantheus Announces Leadership Transition Plan

November 5, 2025

Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

October 29, 2025

Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease

October 27, 2025

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8: 00 a.m. Eastern Time

October 22, 2025

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

September 23, 2025

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 1, 2025

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent

August 5, 2025

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8: 00 a.m. Eastern Time

July 22, 2025

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

July 21, 2025

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

June 10, 2025

Lantheus to Present at the 2025 Truist Securities MedTech Conference

June 9, 2025

Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

June 2, 2025

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

June 2, 2025

Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Lantheus Announces Sale of SPECT Business to SHINE Technologies

May 5, 2025

Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

April 29, 2025

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8: 00 a.m. Eastern Time

April 22, 2025

Lantheus Completes Acquisition of Evergreen Theragnostics

March 31, 2025

Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance

February 25, 2025

Lantheus to Present at Upcoming Investor Conferences

February 20, 2025

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8: 00 a.m. Eastern Time

February 11, 2025

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

February 4, 2025

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

January 29, 2025

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

January 27, 2025

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market

January 12, 2025

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.